MiNK Therapeutics (INKT) Stock Research

MiNK Therapeutics

· INKT

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

63.011 M

-1.61%

Today

MiNK Therapeutics to present data on cancer research at SITC 2026

INKT

9:27 AM

Wednesday

MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy

INKT

Sep 30, 8:07 AM

Over a week ago

MiNK Therapeutics presents early observations from Phase 2 agenT-797 trial

INKT

Aug 6, 12:04 PM

MiNK Therapeutics doses first patient in agenT-797 trial

INKT

May 28, 9:34 AM

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

INKT

May 20, 11:10 AM

MiNK Therapeutics initiates agenT-797 clinical trial

INKT

May 14, 7:47 AM

MiNK Therapeutics management to meet virtually with B. Riley

INKT

Apr 20, 1:03 PM

MiNK Therapeutics announces strategic collaboration with C-Further

INKT

Mar 10, 5:36 AM

MiNK Therapeutics announces new invariant natural killer T cells data

INKT

Feb 4, 5:24 AM

MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial

INKT

Jan 8, 12:06 PM

MiNK Therapeutics announces publication of new preclinical data for MiNK-215

INKT

Nov 20, 11:44 AM

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

INKT

Nov 14, 7:31 AM

MiNK Therapeutics files $150M mixed securities shelf

INKT

Nov 7, 4:58 PM

MiNK Therapeutics reports updated clinical results on agenT-797

INKT

Nov 7, 9:03 AM

No more stories

Charts